Miércoles, 22 Noviembre, 2017

Tale of the Tape: Novavax, Inc. (NASDAQ:NVAX) Moves 4.00%

Manuel Armenta | 20 May, 2017, 11:39

Seven research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.16. Piper Jaffray had a markedly different take on 16/09/2016, proposing that Novavax, Inc.is now considered Neutral versus prior Overweight rating. Tracking most recent quarter period, Price to cash per share ration is at 1.35. Overall, the share price is down -14.76% year to date. Ladenburg Thalmann Financial Services reaffirmed a "neutral" rating on shares of Novavax in a report on Wednesday, March 1st.

Novavax, Inc. (NASDAQ:NVAX) closed at $1.09 gaining 5.83% on a volume of 4.52 million shares. Zacks Investment Research cut shares of Novavax from a "hold" rating to a "sell" rating in a report on Saturday, January 21st. Finally, State Street Corp boosted its stake in Novavax by 99.2% in the fourth quarter. Following the completion of the transaction, the insider now directly owns 128,279 shares of the company's stock, valued at $107,754.36. HighTower Advisors LLC boosted its position in Novavax by 3.8% in the first quarter. Piermont Capital Management Inc. now owns 158,788 shares of the biopharmaceutical company's stock worth $330,000 after buying an additional 13,370 shares during the last quarter. KCG Holdings Inc. boosted its position in Novavax by 161.0% in the first quarter. Institutional investors own 60.36% of the company's stock. Currently Novavax, Inc. (NVAX) has beta value of 2.09. The consensus recommendation for stock is 2.70. If you are reading this report on another publication, it was copied illegally and republished in violation of global copyright and trademark laws.

Novavax (NASDAQ:NVAX) traded down 1.5561% during trading on Tuesday, hitting $0.8161. (NASDAQ:NVAX) to post earnings per share of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. 2,151,689 shares of the company's stock were exchanged.

Novavax, Inc. (NVAX)'s distance from 200 day simple moving average is -56.05 percent, its distance from 50 day simple moving average is -2.85 percent, while its distance from 20 day simple moving average is 20.61 percent. The current share price indicates that stock is -87.16% away from its one year high and is moving 49.32% ahead of its 52-week low.

Best time to invest in stock market is when things are on odd side, and it's not easy how to pick stocks.

Previously Novavax Inc (NASDAQ:NVAX) reported $-0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.17 by $0.01. Novavax had a negative return on equity of 189.14% and a negative net margin of 1,908.41%. According to these analysts, the Low Revenue Estimate for Oclaro, Inc.is 145.96 Million and the High Revenue Estimate is 149 Million. The difference between the expected and actual EPS was $0.03/share, which represents an Earnings surprise of 15%. The firm's revenue for the quarter was up 34.6% compared to the same quarter previous year.

Shares outstanding are recorded as 261.60 M and total shares floated are 261.60 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 1.50.

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

The decrease was primarily due to reduced costs associated with the clinical trials and development activities of our RSV F Vaccine and lower employee-related costs.